Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CDXCNASDAQ:CRONOTCMKTS:CURLFOTCMKTS:STDAF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCDXCChromaDex$6.16$2.31▼$9.18$611.50M2.21818,844 shs554,788 shsCRONCronos Group$1.91$1.92$1.60▼$2.54$736.65M1.041.35 million shs1.11 million shsCURLFCuraleaf$0.82-0.4%$0.87$0.68▼$4.45$546.65M0.59334,498 shs787,511 shsSTDAFSTADA Arzneimittel Aktiengesellschaft$110.42$110.42$75.15▼$115.00$6.88B0.38180 shsN/AA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCDXCChromaDex0.00%0.00%0.00%0.00%+186.00%CRONCronos Group0.00%-4.02%-8.61%+6.70%-17.32%CURLFCuraleaf0.00%-0.05%-5.83%-8.44%-79.14%STDAFSTADA Arzneimittel Aktiengesellschaft0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCDXCChromaDex2.6997 of 5 stars3.50.00.04.00.60.01.9CRONCronos Group2.7754 of 5 stars0.05.00.00.03.30.02.5CURLFCuraleaf2.312 of 5 stars3.52.00.00.02.40.01.3STDAFSTADA Arzneimittel AktiengesellschaftN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCDXCChromaDex 3.00Buy$9.03∞ UpsideCRONCronos Group 0.00N/AN/AN/ACURLFCuraleaf 3.00Buy$6.25658.50% UpsideSTDAFSTADA Arzneimittel Aktiengesellschaft 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCDXCChromaDex$99.60M0.00N/AN/A$0.38 per share0.00CRONCronos Group$117.61M6.26$0.00 per share4,104.70$2.90 per share0.66CURLFCuraleaf$1.34B0.41$0.20 per share4.05$1.51 per share0.55STDAFSTADA Arzneimittel Aktiengesellschaft$3.84B1.79$11.12 per share9.93$23.11 per share4.78Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCDXCChromaDex-$4.94M$0.10787.290.00N/A1.62%4.85%2.70%N/ACRONCronos Group$41.08M$0.1314.6963.6743.3139.69%-0.07%-0.07%8/6/2025 (Estimated)CURLFCuraleaf-$215.42M-$0.31N/AN/AN/A-17.37%-14.12%-4.40%N/ASTDAFSTADA Arzneimittel Aktiengesellschaft$292.15MN/A0.00∞N/AN/AN/AN/AN/ALatest STDAF, CRON, CDXC, and CURLF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025CRONCronos Group$0.01$0.02+$0.01$0.02$45.44 million$33.62 million5/8/2025Q1 2025CURLFCuraleaf-$0.07-$0.07N/A-$0.08N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCDXCChromaDexN/AN/AN/AN/AN/ACRONCronos GroupN/AN/AN/AN/AN/ACURLFCuraleafN/AN/AN/AN/AN/ASTDAFSTADA Arzneimittel AktiengesellschaftN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCDXCChromaDexN/A2.952.35CRONCronos GroupN/A27.8026.75CURLFCuraleaf1.081.410.70STDAFSTADA Arzneimittel Aktiengesellschaft2.231.540.99Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCDXCChromaDex15.41%CRONCronos Group8.71%CURLFCuraleaf0.03%STDAFSTADA Arzneimittel AktiengesellschaftN/AInsider OwnershipCompanyInsider OwnershipCDXCChromaDex9.64%CRONCronos Group7.30%CURLFCuraleafN/ASTDAFSTADA Arzneimittel AktiengesellschaftN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCDXCChromaDex12077.75 million69.02 millionOptionableCRONCronos Group450385.68 million357.53 millionOptionableCURLFCuraleaf5,519663.41 millionN/ANot OptionableSTDAFSTADA Arzneimittel Aktiengesellschaft12,50062.34 millionN/ANot OptionableSTDAF, CRON, CDXC, and CURLF HeadlinesRecent News About These CompaniesFor Faculty & StaffOctober 10, 2024 | smith.eduChicago's GTCR in advanced talks to acquire German drugmakerSeptember 10, 2024 | chicagobusiness.comTrump calls his former chief of staff a ‘terrible, stupid person’August 29, 2024 | msnbc.comStada CEO confirms company may be for saleAugust 6, 2024 | pharmaphorum.comThis week’s deal pipeline: Bain and Cinven consider IPO option for Stada ArzneimittelMay 18, 2024 | penews.comAJMC StaffMay 8, 2024 | ajmc.comWDBJ7 StaffApril 22, 2024 | wdbj7.comSTAFF NEWSFebruary 22, 2024 | washingtonpost.comKPLUY K+S AktiengesellschaftJanuary 10, 2024 | seekingalpha.comKPLUY K+S AktiengesellschaftJanuary 10, 2024 | seekingalpha.comPopSci StaffNovember 24, 2023 | popsci.comBrighton and Hove council staff to receive more moneySeptember 26, 2023 | theargus.co.ukNCR Editorial StaffSeptember 19, 2023 | ncronline.orgStaff SenateAugust 11, 2023 | uwyo.eduSTADA Arzneimittel AG V (SAZA)July 21, 2023 | investing.comWhy are flags at half-staff today in Wisconsin?June 10, 2023 | jsonline.comCBI hired 'toxic' staff and failed to sack offendersMay 30, 2023 | bbc.co.ukWTVY StaffMay 13, 2023 | wtvy.comStaff EditorialsApril 15, 2023 | thegazette.comBA StaffMarch 29, 2023 | baseballamerica.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsMicron Joins Latest $200 Billion United States Investment By Gabriel Osorio-Mazilli | June 16, 2025View Micron Joins Latest $200 Billion United States Investment STDAF, CRON, CDXC, and CURLF Company DescriptionsChromaDex NASDAQ:CDXCChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and Immulina, a spirulina extract with predominant active compounds of Braun-type lipoproteins for supporting human immune function. In addition, it offers phytochemical reference standards, and other research and development services. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation was founded in 1999 and is headquartered in Los Angeles, California.Cronos Group NASDAQ:CRON$1.91 0.00 (0.00%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$1.93 +0.02 (+1.05%) As of 06/18/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.Curaleaf OTCMKTS:CURLF$0.82 0.00 (-0.36%) As of 06/18/2025 03:49 PM EasternCuraleaf Holdings, Inc. operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles. It also provides hemp-based products and cannabinoids, such as cannabidiol and cannabigerol. In addition, the company engages in the cultivation, production, and sale of cannabis products through retail and wholesale channels. The company is headquartered in New York, New York.STADA Arzneimittel Aktiengesellschaft OTCMKTS:STDAF$110.42 0.00 (0.00%) As of 10/24/2022STADA is a publicly traded, international company with a focus on the healthcare market, especially the pharmaceutical and in particular the generics market. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Chime’s Smart IPO: Half the Valuation, Double the Strength 3 Tech Stocks With High and Rising Institutional Interest Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
